Global Cancer Biomarkers Market 2012-2016

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Cancer Biomarkers market has also been witnessing the trend of the emergence of personalized medicines. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market. 

TechNavio's report, the Global Cancer Biomarkers market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Abbott Laboratories, Affymetrix, Inc., Agilent Technologies Inc., Gen-Probe Inc., Hologic, Inc., and Roche Diagnostics Corp.

The other vendors mentioned in the report are Agendia BV, Ambrilia Biopharma, Astellas Pharma US Inc., Morphotek, Inc., Gen-Probe, Inc., Veridex LLC, Morphotek, Inc., Immunomedics, Inc., Clarient, Inc.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?